Under the terms of the agreement, Health Discovery Corporation (HDC) will receive payments, royalties and additional undisclosed financial considerations.
Stephen Barnhill, chairman and CEO of HDC, said: “We are pleased to work with Quest Diagnostics on the development of an exciting new noninvasive test for clinically significant prostate cancer. It is an ideal clinical laboratory to use our markers for developing a test as an aid in detecting prostate cancer.”